Abstract:Dientamoeba fragilis is a ubiquitous intestinal parasite with detection in the stools that has become increasingly frequent following the advent of PCR as a routine screening tool. However, the pathogenicity of this parasite is still much debated. In order to assess the potentially pathogenic nature of this protozoan, a retrospective case-control study was carried out between January and December 2020 on patients from Toulouse University Hospital, with the aim of evaluating the potential clinical effects and changes in laboratory parameters linked to the presence and load of D. fragilis in stools. After matching age, sex and mode of care (consultation or hospitalisation), no significant difference was observed in the frequency of clinical signs between the 36 patients who tested positive for Dientamoeba fragilis PCR in their stools and the 72 control patients who were PCR negative for this protozoan. The presence of D. fragilis in the faeces was not associated with changes in laboratory parameters. Furthermore, a high digestive load of D. fragilis had no identifiable impact on clinical and laboratory parameters. Only the concomitant presence of Blastocystis sp. in stools was significantly more frequent in the D. fragilis group (uni- and multivariate analysis). Finally, this study showed no significant difference in clinical or laboratory signs between patients carrying Dientamoeba fragilis and the control group, regardless of the intestinal parasite load, suggesting that D. fragilis could be considered a commensal of the digestive tract. Dientamoeba fragilis est un parasite digestif ubiquitaire dont la détection dans les selles est devenue de plus en plus fréquente avec l'avènement de la PCR comme outil de détection de routine. Cependant, la pathogénicité de ce parasite est encore très discutée. Afin d'évaluer le caractère potentiellement pathogène de ce protozoaire, une étude rétrospective cas-témoins a été réalisée entre janvier et décembre 2020 sur des patients du CHU de Toulouse, dans le but d'évaluer les effets cliniques et biologiques potentiels associés à la présence et à la charge de D. fragilis dans les selles. Après appariement sur l'âge, le sexe et le mode de prise en charge (consultation ou hospitalisation), aucune différence significative n'a été observée dans la fréquence des signes cliniques entre les 36 patients testés positifs pour la PCR de Dientamoeba fragilis dans les selles et les 72 patients témoins avec une PCR négative pour ce protozoaire. La présence de D. fragilis dans les selles n'était pas associée à des modifications des paramètres biologiques. De plus, une charge digestive élevée de D. fragilis n'avait pas d'impact identifiable sur les paramètres cliniques et biologiques. Seule la présence concomitante de Blastocystis sp. dans les selles était significativement plus fréquente dans le groupe D. fragilis (analyse uni- et multivariée). En conclusion, cette étude n'a pas montré de différence significative concernant les signes cliniques ou biologiques entre les patients porteurs de Dientamoeba fragilis et le groupe témoin, quelle que soit la charge parasitaire digestive, indiquant que D. fragilis pourrait être considéré comme un commensal du tube digestif.

Dientamoeba fragilis in children: a systematic review on diagnostic considerations and efficacy of treatment

No evidence of pathogenicity of Dientamoeba fragilis following detection in stools: A case-control study

A prospective analysis of clinical and parasitological outcomes after treatment or a wait-and-see approach of Dientamoeba fragilis infection in an adult general practice population

Dientamoeba fragilis, the Neglected Trichomonad of the Human Bowel

A Mexican Honeymoon Marred by Gastrointestinal Upset: A Case of Dientamoeba fragilis Causing Post-infectious Irritable Bowel Syndrome

Faecal microbiota transplantation in children: A systematic review

Guidelines for the treatment of dysentery (shigellosis): a systematic review of the evidence

Diagnosis and treatment of severely malnourished children with diarrhoea

Giardia and growth impairment in children in high-prevalence settings: consequence or co-incidence?

Azithromycin for Bacterial Watery Diarrhea: A Reanalysis of the AntiBiotics for Children With Severe Diarrhea (ABCD) Trial Incorporating Molecular Diagnostics

Azithromycin Treatment Response as a Probe to Attribute Bacterial Aetiologies of Diarrhoea using Molecular Diagnostics: A Reanalysis of the AntiBiotics for Children with severe Diarrhoea (ABCD) Trial

Detection of Blastocystis sp. and Dientamoeba fragilis using conventional and molecular methods in patients with celiac disease

Clostridioides difficile Infections: Prevention and Treatment Strategies

Clostridioides difficile Infections in Children: What Is the Optimal Laboratory Diagnostic Method?

Real-Time Multiplex Polymerase Chain Reaction with High-Resolution Melting-Curve Analysis for the Diagnosis of Enteric Infections Associated with Diarrheagenic Escherichia coli

[Advances in the treatment of Clostridium difficile infection in children]

Systematic Review: Faecal Microbiota Transplantation Therapy for Digestive and Nondigestive Disorders in Adults and Children

Clostridioides difficile detection and infection in children: are they just small adults?

Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent Clostridioides difficile Infection

Evaluation of the Allplex GI Parasite and Helminth PCR Assay in a Belgian Travel Clinic

Characteristics and Management of Children with Clostridioides Difficile Infection at a Tertiary Pediatric Hospital in China.